LONDON, Sept. 16,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, today announced that it has
entered into an extension of its already existing exclusive
distribution agreement with Cosmos Health Inc. (Nasdaq: COSM)
("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits
in countries in the Gulf Cooperation Council ("GCC"). It had
previously signed an agreement for exclusive distribution in
Greece & Cyrprus and
non-exclusive distribution throughout Europe.
The RT PCR Mpox virus detection kits are CE-marked for sale in
Europe and also authorized by the
Medicines and Healthcare products Regulatory Agency (MHRA), the
product regulatory agency for the United
Kingdom. These tests perform with a sensitivity of 96.7% and
specificity of 93.72%, with the ability to deliver results in under
70 minutes.
"We are excited to strengthen our partnership with Cosmos. This
exclusive agreement expands our geographic reach, providing a wider
network of healthcare professionals with essential tools to
diagnose and manage the spread of the Mpox virus," James Foster, CEO of Virax Biolabs. "We look
forward to working closely with Cosmos and leveraging its
impressive distribution infrastructure."
"We are happy to further partner with Virax Biolabs as the
Company works diligently to mitigate the spread of Mpox and other
infectious diseases," commented Greg
Siokas, Chief Executive Officer of Cosmos. "We continue
to see strong demand for Mpox virus detection kits, and we believe
that we are well positioned to support Virax and territories in
need."
Under the terms of the agreement, Cosmos is authorized to
import, sell and distribute Virax-branded Mpox virus Nucleic Acid
Detection Kits in the GCC including Bahrain, Kuwait, Oman,
Qatar, Saudi Arabia, and the United Arab Emirates.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-viral syndromes such as Long COVID and other
chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in
Nevada, is a diversified,
vertically integrated global healthcare group. The Company owns a
portfolio of proprietary pharmaceutical and nutraceutical brands,
including Sky Premium Life®, Mediterranation®, bio-bebe® and
C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed
under European Good Manufacturing Practices (GMP) and certified by
the European Medicines Agency (EMA), it manufactures
pharmaceuticals, food supplements, cosmetics, biocides, and medical
devices within the European Union. Cosmos Health also distributes a
broad line of pharmaceuticals and parapharmaceuticals, including
branded generics and OTC medications, to retail pharmacies and
wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company
has established R&D partnerships targeting major health
disorders such as obesity, diabetes, and cancer, enhanced by
artificial intelligence drug repurposing technologies, and focuses
on the R&D of novel patented nutraceuticals, specialized root
extracts, proprietary complex generics, and innovative OTC
products. Cosmos Health has also entered the telehealth space
through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution
platform, the Company is currently expanding throughout
Europe, Asia, and North
America, and has offices and distribution centers in
Thessaloniki and Athens, Greece, and in Harlow, UK. More
information is available at
www.cosmoshealthinc.com, www.skypremiumlife.com, www.zipdoctor.co,
as well as LinkedIn and X.
Investor Relations Contact:
Russo Partners,
LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-extension-of-existing-exclusive-distribution-agreement-to-market-mpox-formerly-monkeypox-virus-real-time-pcr-detection-kits-with-cosmos-health-inc-302248980.html
SOURCE Virax Biolabs